Clinical Manifestation
Approximately half of these aneurysms present with SAH or symptoms caused by mass
effect, while the other half are found incidentally.[8] SAH is often a catastrophic event. Around 20 to 25% of patients succumb before arriving
at the hospital, and among those who do receive timely medical care, only about one-third
experience a favorable outcome posttreatment.[9]
[10] Most SAHs result from ruptured intracranial saccular (berry) aneurysms.[11]
[12]
Diagnosis
The majority of cerebral aneurysms are unruptured and are asymptomatic clinically.
However, a ruptured cerebral aneurysm presents with a sudden-onset headache, which
is severe in intensity (thunderclap headache). In approximately 30% of cases, the
pain tends to be localized on the ipsilateral side. Sudden death can happen in 10
to 15% of patients. Physical examination may reveal signs of raised ICT, i.e., elevated
blood pressure, dilated pupils, visual field or cranial nerve deficits, etc. The Hunt
and Hess grading system, commonly used to predict patient outcomes based on their
initial neurological status, consists of five grades, reflecting symptoms' severity
and correlating with mortality rates.[2] While most aneurysms are discovered in the context of an SAH, unruptured aneurysms
can also be detected in patients presenting with other clinical symptoms or incidentally
through neuroimaging. Unruptured cerebral aneurysms are often detected on magnetic
resonance imaging, computed tomography angiography (CTA), or conventional angiography;
however, ruptured aneurysm resulting in SAH can be detected on a noncontrast CT brain.
Once SAH is diagnosed, the bleeding source must be identified through CTA, magnetic
resonance angiography, or digital subtraction angiography.[2]
Treatment
The management of the ventral ICA aneurysm can be broadly divided into two approaches:
open surgical and endovascular approach. Anatomical factors—including size and location—and
other shape-related characteristics often play a crucial role in determining the most
suitable treatment for a patient.
Microsurgical Approach
The surgical management of cerebral aneurysms, involving the placement of a clip across
the aneurysm neck, can be used in both unruptured or ruptured aneurysms.
It involves ipsilateral pterional craniotomy followed by removal of the anterior clinoid
process, extradural drilling of the optic strut, and then linear dural opening along
the Sylvian fissure, which is followed by distal dural ring dissection, then proximal
dural ring dissection and lastly application of clip under the ventral ICA.
For aneurysms projecting inferiorly or medially, extradural clinoidectomy is safe
and may require less time than intradural clinoidectomy.
Inferiorly projecting aneurysms can be clipped with an up-curved clip rather than
the usual fenestrated clips.
Clipping requires complete visualization of the aneurysm, so the rate of intraoperative
difficulties and complications like inadequate exposure, injury to brain tissue, vessel
injury leading to hemorrhage, and vessel occlusion causing ischemia is relatively
high. Kang et al, in a retrospective analysis of cases undergoing surgical clipping,
found a notable 19.35% incidence of periprocedural technical complications.[13]
Clipping lowers the incidence of residual and recurrent aneurysms. Akyüz et al followed
136 patients with 166 aneurysms at an average of 46.6 months after surgery and found
that 5.1% of aneurysms had residuals.[14] Still, no recurrences were observed, and Brown et al, in 431 ruptured and 327 unruptured
aneurysms, found that 7.8% had residual aneurysms on early postoperative imaging after
1 month, with a single recurrence detected at an average of 7.2 years post-discharge.[15]
Several studies were conducted to assess survival, morbidity, and mortality rates
associated with surgical clipping for unruptured aneurysms. Britz et al, in a retrospective
study, found higher survival rates among patients who underwent clipping, with a 2.3%
risk of death due to neurological causes.[16] The ISUIA, led by Wiebers et al, reported an overall morbidity and mortality rate
of 11 to 13.7% and 10.1 to 12.6% at 30 days and 1-year post-surgery, respectively.[3] In a study, Ogilvy and Carter found an overall mortality rate of 0.8% and a morbidity
rate of 15.9%.[17] Morbidity in these studies encompassed long-term neurological deficits, residual
or reformed aneurysms, bleeding, and ischemic stroke due to vessel occlusion.
Mortality and morbidity rates significantly increase when a ruptured aneurysm is treated
through surgical clipping. According to the International Subarachnoid Aneurysm Trial,
a randomized controlled trial conducted by Molyneux et al, the combined morbidity
and mortality rate was 30.6% in the surgical treatment group. Additionally, the trial
demonstrated an absolute risk reduction of 6.9% in dependency or death among those
treated surgically.[18]
The volume of cases an institution handles also influences the procedure's success.
Rinaldo et al discovered a negative correlation between case volume and complication
rates.[19] Barker et al conducted a retrospective cohort study. They found that high-volume
hospitals, which treated 20 or more cases annually, discharged 84.4% of patients and
had a mortality rate of 1.6%. In contrast, low-volume hospitals (handling fewer than
four cases per year) discharged 76.2% of patients and had a higher mortality rate
(2.2%).[20]
With the advent of less invasive procedures like coil embolization, surgical clipping
has become less prominent in managing intracranial aneurysms. Despite ongoing advancements
in transcranial approaches and clipping techniques, coiling has emerged as the preferred
treatment option in many institutions; nonetheless, clipping remains essential when
coiling is not feasible, such as in cases involving very large aneurysms.[21]
Endovascular Approach
There are various types of endovascular approaches, including coil embolization and
newer techniques like stent-assisted coiling, balloon-assisted coiling (BAC), flow
diverters (FDs), disruptors, and new embolic materials.
Coil embolization involves the insertion of platinum coils into the aneurysm's lumen, forming a local
thrombus around the coils, effectively obliterating the aneurysmal sac. The procedure
begins with gaining vascular access, usually through a peripheral artery like the
femoral artery, and then locating the aneurysm, followed by inserting a detachable
platinum coil in the aneurysm. Once the coil is placed in the aneurysm, clot formation
is triggered. It is followed by dye injection to look for any position of the coil,
condition of the parent artery, and residual blood flow to the aneurysm. The procedure
can be performed under general anesthesia or sedation.[22]
[23]
Coiling is a relatively new approach to treating intracranial aneurysms. The Guglielmi
detachable coil was developed and approved in the 1990s for unruptured aneurysms after
a study by Eskridge and Song, who examined 150 cases of both ruptured and unruptured
aneurysms that were unsuitable for surgical intervention. They suggested that selected
patients (not candidates for clipping) had better outcomes regarding reduced morbidity
and mortality than those managed conservatively.[24]
The Raymond-Roy Occlusion Classification (RROC) is the standard method for evaluating
the success of coiled aneurysms.[25] Mascitelli et al refined RROC and divided class III into classes IIIa and IIIb.
They found that class IIIa aneurysms had a significantly higher likelihood of progressing
to class I or II than class IIIb aneurysms (83.3 vs. 14.9%).[25]
Since its initiation, the coiling technique has undergone substantial advancements.
Nguyen et al assessed aneurysms treated with coiling between 1992 and 2007 and found
a rupture rate of 11.7% in very small aneurysms 3 mm or smaller, compared with just
2.3% in larger aneurysms.[21]
[26]
Advances such as softer and smaller coils (around 1 mm in diameter) have made it safer
to treat smaller aneurysms. In contrast, larger diameter coils have been developed
to pack larger aneurysms more efficiently.[27]
The Analysis of Treatment by Endovascular Approach of Unruptured Aneurysms (ATENA)
study, led by Pierot et al. (2008), assessed the effectiveness, morbidity, and mortality
rates of coiling in a multicentric prospective study involving 649 patients with 1,100
unruptured aneurysms. They found that procedure-related adverse events occurred in
15.4% of patients, and morbidity and mortality rates after 1 month were 1.7 and 1.4%,
respectively. They concluded that coiling has low morbidity and mortality rates.[28]
Numerous studies have explored the safety and effectiveness of coiling, but all found
that coiling has a low rate of complete occlusion. Gallas et al reported a 70% immediate
total occlusion rate in a retrospective study, with a 26.1% subtotal occlusion rate
and 14.4% treatment-related morbidity.[29] Similarly, Bradac et al reported a 64% complete occlusion rate, a 34% nearly complete
rate, and a 13% complication rate.[30] Murayama et al reported a 55% complete occlusion rate and a 35.4% neck remnant rate,
with a 20.9% recanalization rate primarily linked to the size of the aneurysm's dome
and neck and 1.6% delayed aneurysm rupture.[31] The ISUIA found that treatment-related morbidity and mortality were higher in patients
with prior SAH than in those without (9.8 vs. 7.1%).[3]
Stent-assisted embolization as a treatment for intracranial aneurysms was first introduced by Henkes et al in
a multicentric prospective study.[32]
It was the initially accepted treatment method for unruptured ICA aneurysms with a
broad neck and unfavorable neck-to-fundus ratio (dome-to-neck ratio less than 2 or
a neck length of 4 mm or more). It was challenging to treat by surgical or traditional
coiling. Stent-assisted coil embolization facilitates proper coil placement while
preventing the coils from protruding into the parent vessel. Moreover, intracranial
stents may reduce the likelihood of aneurysm recanalization.[33] Stents are positioned in the artery, so antiplatelet regimens are required to prevent
arterial thromboembolic complications, making using stents more challenging in cases
of recently ruptured aneurysms.[34]
Bechan et al, in a prospective observational study on 45 patients with ruptured and
47 patients with unruptured aneurysms, found that complication rates like visible
thrombus, vessel occlusion, and rebleeding were 10 times more common when stent-assisted
coil embolization was done in ruptured aneurysm as compared with unruptured aneurysm.[35]
Recently, its use has expanded to treat all types of aneurysms.[34] Coiling is performed mainly under general anesthesia.
First, stent placement is simulated using computer graphics on a three-dimensional
dataset with standard machine software. The software accurately calculated the diameters
and lengths of the targeted vessel segment, allowing for the selection of the appropriate
stent size and length. A microcatheter is used to navigate past the aneurysm. After
placing the stent, the delivery microcatheter is removed, and a lower profile microcatheter
is introduced through the stent struts into the aneurysm. Coils are then deployed
to occlude the aneurysm.[35]
In a randomized clinical trial, Boisseau et al assessed the superiority of stent-assisted
coiling over coiling alone in treating unruptured cerebral aneurysms in a 10-year
study on 205 patients. They found that stent-assisted coiling did not offer any advantage
over traditional coiling in terms of recurrence of the lesions, intracranial bleeding,
retreatment, modified Rankin scale of 3 to 5, or death.[34]
Newer endovascular techniques have emerged that may complement or replace coiling.
Liquid embolic, particularly Onyx HD-500, has gained attention for treating wide-neck
aneurysms.[27] Dalyai et al achieved a 90% complete occlusion rate in patients with wide-neck aneurysms
who could not be coiling alone.[36]
Additional innovations, including endoluminal flow diversion and aneurysmal neck reconstruction,
are being evaluated as treatment options.[37]
[38]
Balloon-assisted coiling, also known as the remodeling technique, was first introduced by Moret et al to extend
endovascular treatment (EVT) to wide-neck intracranial aneurysms. In this technique,
a nondetachable balloon is temporarily inflated across the aneurysm neck during the
placement of each coil. The balloon is positioned within the parent vessel adjacent
to the aneurysm neck for sidewall aneurysms. Once the coiling is completed, the balloon
is deflated and removed unless stenting is required as a follow-up procedure.[39]
[40] A 2006 single-center retrospective study on both ruptured and unruptured aneurysms
suggested that BAC was linked to a higher complication rate. Specifically, the rates
of thromboembolic events and intraoperative ruptures in the BAC group were 9.8 and
4.0%, respectively, compared with 2.2 and 0.8% in the coiling-alone group.[41] However, more recent data from two large multicenter prospective studies have provided
a clearer picture. In the ATENA study (which focused on unruptured aneurysms), the
rate of thromboembolic events was similar between the BAC group (5.4%) and the coiling-alone
group (6.2%).[28]
Additionally, the rate of intraoperative rupture was 3.2% in the BAC group and 2.2%
in the coiling-alone group. Clinical outcomes were also comparable, with a permanent
deficit or death in 0.6% of the coiling group and 1.4% of the BAC group. Morbidity
rates were 2.2% for coiling alone and 2.3% for BAC, while mortality was 0.9 and 1.4%,
respectively.[28]
[42]
In the CLARITY study (which focused on ruptured aneurysms), the two groups' thromboembolic
event rates were similar: 12.7% in the coiling group and 11.3% in the BAC group. The
rate of intraoperative rupture was 4.4% for both groups, with morbidity and mortality
rates being comparable as well.[43]
The impact of BAC on anatomical outcomes remains uncertain. One study found that aneurysms
treated with BAC had a higher rate of incomplete occlusion (27.7%) compared with those
treated with standard coiling (16.9%), as well as a higher rate of retreatment (16.9
vs. 9.0%).[41] However, another series reported better initial and follow-up anatomical results
with BAC. This study achieved total occlusion in 73% of BAC-treated patients postoperatively
compared with 49% with coiling alone, with similar results observed during follow-up.[44] Conversely, the ATENA series on unruptured aneurysms did not show better anatomical
outcomes with BAC.[28]
[42]
BAC was initially developed for wide-neck aneurysms, but it has also demonstrated
utility in cases of intraoperative rupture, where balloon assistance may improve clinical
outcomes.[45] In this scenario, the balloon is left deflated across the aneurysm neck and is only
inflated if rupture occurs, serving as a protective measure. This “sentinel” use of
BAC has contributed to its increased adoption in recent years, with one study showing
a rise in its use from 23.9% in 2008 to 43.9% in 2010.[46] The study also highlighted the versatility of BAC, noting its application in both
ruptured and unruptured aneurysms of various locations, particularly those with an
unfavorable dome-to-neck ratio (≤1.5).[39]
[46]
FDs, developed over the past two decades based on in vivo and in vitro research, were
introduced for clinical aneurysm treatment in the late 2000s. These low-porosity,
stent-like implants work through two primary mechanisms:
-
Flow redirection: the FD is placed across the aneurysm neck, reducing blood flow into
the aneurysm sac by increasing resistance with its mesh structure while still allowing
blood to pass through nearby perforators and side branches. This redirection decreases
circulation within the aneurysm, leading to flow stasis and the formation of a stable
thrombus inside the aneurysm.
-
Tissue overgrowth: the FD acts as a scaffold, encouraging neoendothelialization over
the aneurysm neck, which helps further seal the aneurysm.[47]
[48]
Preclinical studies have shown FDs to be effective and safe in treating aneurysms
with reasonable occlusion rates and fewer thromboembolic complications.[49]
[50]
Initially, two FDs were available: the Pipeline Embolization Device (EV3-MTI, Irvine,
California, United States) and Silk (Balt, Montmorency, France). Recently, other devices
like Surpass (Stryker, Fremont, California, United States) and FRED (Microvention,
Tustin, California, United States) have been introduced.[51]
[52]
[53]
[54]
[55] Early clinical experience with FDs, primarily from smaller single-center or multicenter
retrospective studies, demonstrated treatment feasibility, acceptable periprocedural
complication rates, and favorable morbidity and mortality outcomes.[51]
[52]
[53]
[54]
[55] Larger retrospective and prospective series have since confirmed these findings.[56]
[57]
[58]
Flow diversion is typically used for treating complex aneurysms, such as large, giant,
wide-neck, fusiform, or recanalized aneurysms after coiling. A recent international
multicenter prospective study focused on treating complex aneurysms in the intracranial
ICA in 108 patients. The treatment was feasible in 99.1% of cases, achieving complete
occlusion in 73.6% of aneurysms at 180 days without significant vessel stenosis. The
study also showed an acceptable safety profile, with 5.6% of patients experiencing
a major ipsilateral stroke or neurological death.[59]
Although the precise indications for flow diversion are still evolving, clinical experience
has shown that FDs are primarily used for treating large and giant aneurysms (including
fusiform aneurysms), wide-neck aneurysms, aneurysms within diseased arterial segments
with multiple aneurysms, and recurrent aneurysms. Due to the need for dual-antiplatelet
therapy, most aneurysms treated with FD are unruptured. However, small studies have
highlighted the effectiveness of FD in managing very small aneurysms, including blister-like
aneurysms, which are difficult to treat with standard coiling techniques.[60]
As FD use becomes more widespread, more information on potential complications has
emerged. Like other EVTs for aneurysms, thromboembolic events and intraoperative rupture
can occur. The risk of intraoperative rupture is generally lower with FD due to the
absence of endovascular manipulation. Still, the risk of thromboembolic events is
higher than standard coiling or BAC since FD is placed in the parent artery. To reduce
this risk, both preoperative and postoperative antiplatelet therapy (single or dual)
is recommended.
More extensive clinical experience with FD has also revealed complications not typically
seen with standard coiling or BAC, such as delayed aneurysm rupture and remote parenchymal
hematomas. Most of these complications have been reported in large and giant aneurysms,
which have a high natural risk of bleeding and were previously untreatable.[61]
[62]
[63]
[64] The Retrospective Analysis of Delayed Aneurysm Ruptures (RADAR) study showed that
delayed aneurysm rupture occurred in approximately 1% of patients after FD treatment.[65] Turowski et al reported 13 cases of delayed ruptures with the Silk implant, with
early ruptures (within 3 months) occurring more frequently than late ones (after 3
months).[61] Early ruptures occurred between 2 and 48 days posttreatment, with patients typically
still on dual-antiplatelet therapy (aspirin and clopidogrel). Late ruptures, which
occurred in patients only receiving aspirin, were seen between 110 and 150 days posttreatment.
Delayed ruptures were most common in symptomatic, large, or giant aneurysms, particularly
those with high dome-to-neck ratios.[62]
[65]
Another severe complication associated with FD use is delayed ipsilateral parenchymal
hemorrhage, with its incidence varying across studies. In the Cruz et al study, delayed
hemorrhage occurred in 8.5% of patients, while the RADAR study reported a 1.9% incidence.[65]
[66] This complication was observed between 1 and 6 days posttreatment and was associated
with variable clinical outcomes. A separate small series achieved favorable outcomes
following surgical hepatoma evacuation after platelet transfusion. The proposed mechanisms
behind delayed parenchymal hemorrhage include the hemorrhagic transformation of ischemic
lesions, altered intracranial blood pressure in distal territories, and loss of autoregulation
in the distal arteries. Dual-antiplatelet therapy may also contribute to the size
of the hematoma or trigger spontaneous bleeding, similar to what is occasionally seen
after carotid artery stenting.[65]
[66]
Another concern with FD is the patency of perforating arteries and side branches covered
by the device.
Finally, long-term follow-up is necessary to monitor for late thrombosis of FDs, which
has been reported in certain aneurysms.[67]
Flow Disruption
Intravascular flow disruption is an endovascular technique akin to intraluminal FD
technology. The primary distinction lies in placing the flow disruptor's mesh directly
within the aneurysm sac rather than the parent artery. This strategic placement induces
blood flow stasis inside the aneurysm, leading to thrombosis and stabilization of
the aneurysm. Preclinical research has demonstrated that this method is feasible and
practical, with a strong safety profile.[68] In an initial retrospective multicenter study involving 20 patients treated with
the WEB device (Sequent Medical Inc., Aliso Viejo, California, United States), the
treatment achieved a 100% technical success rate, with no mortality and a low % morbidity
rate of 4.8%.[69] Subsequent prospective single-center studies have reported comparable outcomes,
reinforcing the reliability of the WEB device.[70] The preliminary data suggest that the WEB device is particularly suitable for managing
wide-neck bifurcation aneurysms in the basilar artery, middle cerebral artery, anterior
communicating artery, and ICA.[71] A significant advantage of this intravascular approach is that the flow disruptor
remains entirely within the aneurysm, eliminating the need for antiplatelet therapy.[71] This feature makes the technique especially promising for treating ruptured aneurysms.
Additionally, there have been successful applications of the WEB device in treating
recanalized aneurysms, further highlighting its versatility and potential in various
clinical scenarios.[69]